Complete Guide to Stelara (Ustekinumab) Pharmacokinetics
Overview
Stelara (Ustekinumab) is a mAb used in the Immunology therapeutic area. It is indicated for Plaque psoriasis. Simulate Stelara (ustekinumab) pharmacokinetics. This PK simulator models the anti-IL-12/23 p40 monoclonal antibody for psoriasis, psoriatic arthritis, and Crohn's disease.
Mechanism of Action
Stelara (Ustekinumab) exerts its pharmacological effect by targeting IL-12/IL-23 p40. As a mAb, it modulates this target to achieve therapeutic efficacy in Plaque psoriasis. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
This 2-CMT PopPK model for Stelara (Ustekinumab) characterizes the time-course of drug concentrations following SC, IV administration. Key parameters such as clearance (CL), volume of distribution (Vd), and absorption rate constant (Ka) define the drug's disposition. Use the interactive simulator below to explore these parameters in detail.
Dosing & Administration
Stelara (Ustekinumab) is administered via the SC, IV route. Intravenous administration provides 100% bioavailability and allows precise control of drug exposure. Infusion duration and rate can significantly impact peak concentrations.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Immunology therapeutic area, for the treatment of Plaque psoriasis, understanding the pharmacokinetics of Stelara (Ustekinumab) is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Stelara (Ustekinumab) pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
Interactive Stelara (Ustekinumab) PK Simulator
Explore Stelara (Ustekinumab) pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Stelara (Ustekinumab)?
The elimination half-life of Stelara (Ustekinumab) depends on patient-specific factors. Use our interactive Stelara (Ustekinumab) PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is Stelara (Ustekinumab) administered?
Stelara (Ustekinumab) is administered via the SC, IV route. It is indicated for Plaque psoriasis. As a mAb, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Stelara (Ustekinumab)?
Key pharmacokinetic parameters for Stelara (Ustekinumab) include clearance (CL), volume of distribution (Vd), and elimination half-life. Our interactive simulator uses a 2-CMT PopPK model to characterize the pharmacokinetics of Stelara (Ustekinumab).
Can I simulate Stelara (Ustekinumab) dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Stelara (Ustekinumab) PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.